Search
Tyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Benzatropine
go.drugbank.com/drugs/DB00245ApprovedInvestigational[A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500]
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAn aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalOsimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedIt was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.
Cefprozil
go.drugbank.com/drugs/DB01150ApprovedInvestigationalCefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Cenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalCenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis...
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]